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httpOutcomes of carotid endarterectomy versus
stenting in comparable medical risk patients
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Marc L. Schermerhorn,MD,c Richard J. Powell,MD,a JackL. Cronenwett,MD,a andBrianW.Nolan,MD,MS,a
for the Vascular Study Group of New England, Lebanon, NH; and Worcester and Boston, Mass
Objective: In medically high-risk patients the choice between carotid artery stenting (CAS) and carotid endarterectomy
(CEA) can be difﬁcult. The purpose of this study was to compare risk-stratiﬁed outcomes of CAS and CEA.
Methods: Patients who underwent isolated primary CEA (n [ 11,336) or primary CAS (n [ 544) at 29 centers in the
Vascular Study Group of New England were analyzed (2003-2013); patients with previous ipsilateral CEA or CAS, or
concomitant coronary artery bypass graft were excluded. A medical risk score based on predicted 5-year mortality was
developed for each patient using a Cox proportional hazards model. Patients in the highest risk score quartile were termed
high-risk (vs normal-risk for the other three quartiles). Medically high-risk patients had a 5-year survival of 65% and
comprised 23% of CEA and 25% of CAS patients. Risk-stratiﬁed outcomes were compared within neurologically symp-
tomatic and asymptomatic patients.
Results: Among asymptomatic patients, rates of in-hospital stroke and/or death were not different between CAS and CEA
in normal and high-risk cohorts, ranging from 0.7% in normal-risk CEA patients to 1.6% in high-risk CAS patients. In
symptomatic patients, signiﬁcantly worse outcomes were seen with CAS compared with CEA in normal-risk and high-risk
patients. Normal-risk symptomatic patients had a stroke or death rate of 1.3% with CEA, but 5.2% with CAS (P < .01). In
high-risk symptomatic patients, the stroke or death rate was 1.5% with CEA and 9.3% with CAS (P < .01). No signiﬁcant
differences were seen between asymptomatic CEA and CAS within risk strata across secondary outcome measures of
stroke, death, or myocardial infarction, and ipsilateral stroke, major stroke, or death. However, symptomatic high-risk
CAS patients had signiﬁcantly greater rates of all secondary outcomes compared with CEA except death, and symp-
tomatic normal-risk CAS patients had only signiﬁcantly greater rates of death and stroke, death, or myocardial infarction.
Conclusions: In the Vascular Study Group of New England, asymptomatic normal- and high-risk patients do equally well
after CEA or CAS. However, normal- and high-risk symptomatic patients have substantially worse outcomes with CAS
compared with CEA. High medical risk alone might be an insufﬁcient indication for CAS in symptomatic patients. (J Vasc
Surg 2014;60:1227-31.)In 2005, carotid artery stenting (CAS) received Center in patients with high anatomic risk criteria for CEA, such as
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extending proximal to the clavicle or distal to the C2 verte-
bral body.2,3 There has been much greater controversy
over medical high-risk criteria,1,3,4 and it remains unclear
which, if any, patients require carotid revascularization
but are too medically high-risk for CEA, and in whom
CAS is thus preferable.
Comparisons within stratiﬁed medical risk groups have
been undertaken in select nonrandomized settings. Using
the Stenting and Angioplasty with Protection in Patients at
High Risk for Endarterectomy Trial (SAPPHIRE) criteria3
to deﬁne high risk, Mozes et al reviewed their consecutive pa-
tient experience with CEA at a single institution and found no
statistical difference in major stroke and death rates between
their low- or high-risk groups in symptomatic or asymptomatic
patients; from this they advocated the treatment option
of CEA even in SAPPHIRE-eligible patients at high risk.5
More recently, within the Society for Vascular Surgery (SVS)
Vascular Registry, Schermerhorn et al found after adjusting
for symptomatic and high risk status, CAS patients had signif-
icantly greater rates of major adverse events than CEA
patients with no difference in myocardial infarction (MI).4
Randomized controlled trials such as the International
Carotid Stenting Study (ICSS) and the Carotid Revascular-
ization Endarterectomy vs Stent Trial (CREST) have
shown greater 30-day rates of stroke for CAS relative to1227
Table I. Demographic characteristics
CEA
(n ¼ 11,336)
CAS
(n ¼ 544) P
Hypertension 88 88 .78
Tobacco use 79 80 .75
Any CAD 31 43 <.01
Positive stress test 10 14 <.01
CHF 8 18 <.01
Oxygen-dependent COPD 2 5 <.01
IDDM 9 12 .01
Renal insufﬁciency 6 6 .95
Antiplatelet agent 91 96 <.01
b-blocker 75 65 <.01
Statin 79 81 .36
CAD, Coronary artery disease; CAS, carotid artery stent; CEA, carotid
endarterectomy; CHF, congestive heart failure; COPD, chronic obstructive
pulmonary disease; IDDM, insulin-dependent diabetes mellitus.
Data are presented as percentage.
Table II. Comparison of high-risk designations
Medical high-risk designation
Based on VSGNE
mortality risk score
Based on SAPPHIRE
criteria
CEA 23.4 26.6
CAS 25.3 30.8
CAS, Carotid artery stent; CEA, carotid endarterectomy; SAPPHIRE,
Stenting and Angioplasty with Protection in Patients at High Risk for
Endarterectomy Trial; VSGNE, Vascular Study Group of New England.
Data are presented as percentage.
JOURNAL OF VASCULAR SURGERY
1228 Spangler et al November 2014CEA in symptomatic patients.6-8 ICSS excluded patients
with high-risk anatomic criteria or in whom coronary revas-
cularization was anticipated within a month of the proce-
dure9 or by investigator determination of risk factors for
surgical complications6 and CREST excluded patients
with unstable angina or MI within the past 30 days.7,8
The objective of this study was to compare outcomes
of CEA and CAS in comparable medical risk patients using
the Vascular Study Group of New England (VSGNE) reg-
istry to identify opportunities for improving selection for
CAS and CEA.
METHODS
Data were obtained from the VSGNE, a regional co-
operative developed in 2002 to improve vascular surgery
outcomes; details of the database have been previously pub-
lished.10 This database and this study have been approved by
the Institutional Review Board at each of the participating
institutions. Deidentiﬁed CEA and CAS procedures within
the VSGNE from January 2003 to June of 2013 were
analyzed. Patients who underwent concomitant carotid cor-
onary artery bypass graft or with history of previous ipsilat-
eral carotid revascularization were excluded.
The study sample was comprised of 11,880 patients;
11,336 from 29 centers who underwent CEA, and 544
from 15 centers who underwent CAS. CAS procedures,
performed by a mixture of surgeon and nonsurgeon pro-
viders, were ﬁrst recorded in the VSGNE registry in 2005.
The primary study end point was any in-hospital stroke
or death. Secondary outcomes included in-hospital stroke,
death, or MI, ipsilateral stroke (either major or minor), ma-
jor stroke (either ipsilateral or contralateral), anddeath; these
were examined according to risk category and procedure.
Baseline patient characteristics are listed in Table I; pa-
tients who underwent CAS were slightly younger, more often
male, and more often symptomatic. Patients who underwent
CAS similarly had a greater prevalence of oxygen-dependent
chronic obstructive pulmonary disease and insulin-dependent
diabetes mellitus, and a greater burden of cardiovasculardisease, assessed as percent with any coronary artery disease,
positive stress test, or congestive heart failure (CHF).
A Cox proportional hazards model was created using
backwards stepwise regression to model the risk of 5-year
mortality for the cohort as a whole based onmedical risk fac-
tors. This model included advanced age, preoperative ipsilat-
eral neurologic symptoms, oral medication or insulin-treated
diabetes mellitus, any history of tobacco use, oxygen-
dependent chronic obstructive pulmonary disease, CHF,
coronary artery disease, or end-stage renal disease (dialysis
dependence or history of kidney transplantation), lack of a
statin, and lack of antiplatelet agent.11 Risk scores were calcu-
lated for each patient using normalized b coefﬁcients from the
model,12,13 andgrouped into risk quartiles, withhigher scores
having greater risk of long-term mortality (Supplementary
Fig, online only). The 5-year mortalities of the lower three
quartiles of risk score were similar and subsequently classiﬁed
as “normal risk,” for comparisons with the highest risk quar-
tile. The distribution of CEA and CAS within the highest
risk quartile was similar in proportion (23% of CEA and 25%
of CAS); other demographic characteristics of the normal-
and high-risk groups are detailed in the Supplementary
Table (online only). We used 5-year mortality estimates as
the indicator of overall medical risk in this study.
To validate our calculated medical risk score, we
compared the proportion of our sample thatwould be termed
high-riskbasedonourmortality risk scorewith theproportion
having one or more of the medical high-risk criteria from the
SAPPHIRE registry (Table II). Medical components of a
SAPPHIRE high-risk designation included CHF, open-
heart surgery within 6 weeks, recent MI, unstable angina,
abnormal stress test, coexistent severe cardiac and carotid dis-
ease requiring open heart surgery and carotid revasculariza-
tion, severe pulmonary disease, and age $80 years.14,15
Similar proportions of patients were identiﬁed as high-risk us-
ing the SAPPHIRE medical criteria and our mortality-based
score. Additionally, the 5-year survival for patients identiﬁed
as high-risk using the SAPPHIRE medical criteria did not
signiﬁcantly differ from that of our high-risk cohort.
RESULTS
Our retrospective analysis of the VSGNE registry exam-
ined 11,880 patients who received isolated CEA or CAS, of
whom 3960 (33.3%) were symptomatic patients. Among the
7920 asymptomatic patients, 18.5% who received CEA and
Table III. Risk stratiﬁed periprocedural outcomes among asymptomatic patients
Asymptomatic normal-risk Asymptomatic high-risk
CEA (n ¼ 6272) CAS (n ¼ 273) P CEA (n ¼ 1313) CAS (n ¼ 62) P
Stroke or death 0.7 1.1 .49 1.2 1.6 .78
Stroke, death, or MI 1.5 1.1 .57 2.6 1.6 .63
Any ipsilateral stroke (major or minor) 0.5 1.1 .16 0.8 1.6 .52
Any major stroke (ipsilateral or contralateral) 0.4 0.0 .33 0.3 0.0 .66
Death 0.1 0.0 .61 0.4 0.0 .63
CAS, Carotid artery stent; CEA, carotid endarterectomy; MI, myocardial infarction.
Data are presented as percentage, except where otherwise noted.
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the symptomatic patients, 35.7% who received CEA and
35.9% who received CAS were considered high-risk. In
asymptomatic patients, no signiﬁcant difference was seen in
stroke or death rates between those who underwent CEA
and CAS among normal-risk patients (0.7% with CEA,
1.1% with CAS; P ¼ .49) or high-risk patients (1.2% with
CEA, 1.6% with CAS; P ¼ .78; Table III). These results
were consistent with those seen in asymptomatic patients
in the CREST trial, in which there was a 1.4% stroke or death
rate in asymptomatic CEA and 2.5% in asymptomatic CAS
patients (P¼ .15).7,8,16No statistically signiﬁcant differences
were noted between CEA andCAS across any of the second-
ary outcomes, including stroke death or MI, ipsilateral
stroke, major stroke, or death.
Among symptomatic patients, signiﬁcantly worse out-
comes were seen with CAS compared with CEA in
normal-risk and high-risk patients (Fig).7,8,16 Normal-risk
symptomatic patients had a stroke or death rate of 1.3%
with CEA, but 5.2% with CAS (P< .01). In high-risk symp-
tomatic patients, the stroke or death rate was 1.5% with
CEA and 9.3% with CAS (P < .01), and the stroke or death
rate was 3.2% for CEA and 6.0% for CAS (P< .05) in symp-
tomatic CREST patients.7,8,16 Similar trends were seen with
the addition of MI to the combined end point, with signif-
icantly worse outcomes in the CAS group compared with
the CEA group, seen in the normal-risk cohort (2.2%
CEA vs 6.0% CAS) and high-risk cohort (2.5% CEA vs
9.3% CAS). The stroke rate for each procedure did not
signiﬁcantly differ in symptomatic normal-risk patients,
although it approached signiﬁcance for any ipsilateral stroke
at 1.1% with CEA vs 3.0% with CAS; P ¼ .06. However,
among symptomatic high-risk patients, the rates were signif-
icantly greater for CAS for ipsilateral stroke (0.8% with CEA
vs 6.7% with CAS) and any major stroke (0.6% with CEA vs
6.7% with CAS; Table IV). Most of the events that contrib-
uted to stroke, death, or MI were major strokes in symp-
tomatic high-risk patients treated with CAS.DISCUSSION
Comparing CEA and CAS results in real-world practice
has often been plagued by the question of whether one
group of patients bears a greater disease or comorbidity
burden. Although it is commonly accepted that high-riskanatomic factors make CAS a preferred treatment option
compared with CEA, the choice between CAS and CEA
for carotid revascularization in medical high-risk patients
is less clear. By stratifying patients according to symptom-
atic status and medical risk status, our analysis allows for
comparisons between procedures within groups at similar
risk of mortality.
Previous work has been done to stratify medical risk of
patients who undergo vascular procedures11,12; this is
important in making treatment selections. Wallaert et al
found among asymptomatic high-risk patients in the
VSGNE, 5-year survival after CEA was only 51%, and
that 20% of asymptomatic patients who underwent CEA
had poor predicted long-term survival.11 These patients
fared worse, even in the postoperative period, experiencing
signiﬁcantly greater rates of postoperative stroke and death
than their normal medical risk counterparts.11 This sug-
gests the need to avoid any intervention in high-risk asymp-
tomatic patients not anticipated to live long enough to
receive beneﬁts from a prophylactic procedure. Mozes
et al, in a single-center consecutive CEA patient experience
of symptomatic and asymptomatic patients, found no sta-
tistical difference in major stroke and death rates between
low- and high-risk patients (based on SAPPHIRE criteria),
although the combined stroke death or MI rate was signiﬁ-
cantly lower in low-risk symptomatic patients.5 A retrospec-
tive study by Gasparis et al, who examined consecutive
isolated CEAs at two hospitals with a smaller proportion
identiﬁed as high risk, came to similar conclusions.17 These
studies have raised the question of whether, based on antic-
ipated procedural outcomes, patients exist who are too high
risk for CEA but appropriate for CAS.5,17
Review of the VSGNE registry participants suggest
signiﬁcantly worse outcomes in periprocedural stroke,
and combined outcomes of stroke or death, and stroke
death or MI in symptomatic patients receiving CAS, partic-
ularly among medically high-risk patients. Our societal
guidelines suggest CAS as an alternative to CEA for symp-
tomatic patients at average or low risk of complications
associated with endovascular intervention, with internal ca-
rotid stenosis >70% determined using noninvasive imaging
or >50% using angiography with an anticipated rate of
periprocedural stroke or mortality <6%.2,18 Within our
cohort, the 9.3% periprocedural stroke or death rate in
symptomatic high-risk patients failed to meet this threshold.
Fig. Stroke or death in symptomatic patients comparied with Carotid Revascularization Endarterectomy vs Stenting
Trial (CREST) ﬁndings.8 CAS, Carotid artery stenting; CEA, carotid endarterectomy; VSGNE, Vascular Study Group
of New England.
Table IV. Risk stratiﬁed periprocedural outcomes among symptomatic patients
Symptomatic normal-risk Symptomatic high-risk
CEA (n ¼ 2412) CAS (n ¼ 134) P CEA (n ¼ 1339) CAS (n ¼ 75) P
Stroke, death, or MI 2.2 6.0 <.01 2.5 9.3 <.01
Any ipsilateral stroke (major or minor) 1.1 3.0 .06 0.8 6.7 <.01
Any major stroke (ipsilateral or contralateral) 0.5 1.5 .10 0.6 6.7 <.01
Death 0.2 2.2 <.01 0.5 1.3 .36
CAS, Carotid artery stent; CEA, carotid endarterectomy; MI, myocardial infarction.
Data are presented as percentage, except where otherwise noted.
JOURNAL OF VASCULAR SURGERY
1230 Spangler et al November 2014Similar ﬁndings were encountered by Giles et al among
symptomatic high-risk patients within a 2004 to 2007 na-
tional inpatient sample cohort in which symptomatic high-
risk CAS patients had a 14.4% periprocedural stroke or death
rate.19
Our study has several limitations including relatively low
event rates, potential selection bias, and possible confound-
ing related to operator volume or changes in outcomes over
time. Although we demonstrated a signiﬁcantly greater
stroke or death rate in symptomatic high-risk patients who
received CAS compared with CEA, the underlying rates
might be even greater. The VSGNE has the potential to un-
derestimate events because only clinically evident stroke and
MI are tracked and periprocedural outcomes in VSGNE
extend only within the index hospitalization. It is estimated
that approximately a third of strokes and cardiac events
occur after hospital discharge in symptomatic and asymp-
tomatic patients.20 However, we would expect the trend
of worse outcomes with CAS compared with CEA in symp-
tomatic patients to persist, as the Endarterectomy versus
Angioplasty in Patients with Symptomatic Severe Carotid
Stenosis (EVA-3S) investigators noted a signiﬁcantly greaterproportion of strokes occurred on the day of the procedure
in patients who received CAS rather than CEA.21 Similarly,
Sidaway et al, in examining predischarge vs 30-day out-
comes of CEA and CAS, found that an additional 1.79%
combined stroke death orMI events take place after hospital
discharge from CAS, but only an additional 0.58% occur af-
ter CEA.22
Other possibilities for discrepancies in event rates be-
tween our registry ﬁndings and previous trial results include
patient and provider selection. Providers within CREST
were selected for having previous complication and death
rates of less than 3% among asymptomatic patients and
less than 5% among symptomatic patients.7 The highly
controlled patient and provider environment of the trials
would therefore be expected to yield lower adverse outcome
rates compared with routine clinical practice. However,
because of the similarity of CEA adverse event rates seen in
registry and trial data, the signiﬁcantly greater adverse event
rates observed among CAS patients remains a concern.
Additionally, although our data span a decade time-
frame, no systemic early-adopter or provider volume bias
was evident, with event rates stable across time within
JOURNAL OF VASCULAR SURGERY
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higher CAS event rates (which corresponded with a greater
total number of procedures performed that year). No
trends were noted among stroke or death rates and
methods of embolic protection in CAS, although a com-
parison across types of embolic protection was underpow-
ered because of the relatively small number of CAS
procedures. Additionally, reanalyzing the data excluding
the years 2003 and 2004, in which no CAS procedures
were recorded, did not affect our ﬁndings.
CONCLUSIONS
Although symptomatic medical high-risk patients are a
group in whom CAS is a potentially alluring treatment op-
tion, knowledge of local rates of periprocedural adverse out-
comes should factor into physician treatment decisions. CAS
might be inappropriate for symptomatic high medical risk
patients without anatomic indications. In the VSGNE,
CEA is the more appropriate intervention for these patients.
These results highlight the importance of quality improve-
ment registries in tracking real-world results which might
differ from those of randomized controlled trials.
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Supplementary Fig (online only). Risk-stratiﬁed quartiles of survival deﬁning normal- and high-risk cohorts. VSGNE,
Vascular Study Group of New England.
Supplementary Table (online only). Distribution of
demographic characteristics according to risk group
Normal-risk
(n ¼ 9091)
High-risk
(n ¼ 2795) P
Mean age (standard deviation) 68 (9) 76 (8) <.01
Hypertension 87 91 <.01
Tobacco use 78 84 <.01
Any CAD 25 55 <.01
Positive stress test 9 14 <.01
CHF 3 24 <.01
Oxygen-dependent COPD 0.3 6 <.01
IDDM 7 18 <.01
Renal insufﬁciency 2 18 <.01
Antiplatelet agent 95 79 <.01
b-blocker 73 78 <.01
Statin 86 56 <.01
CAD, Coronary artery disease; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; IDDM, insulin-dependent diabetes
mellitus.
Data are presented as percentage, except where otherwise noted.
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